A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-ThalassemiaMaria Domenica Cappellini, Antonio Piga, Vip Viprakasit et al.|New England Journal of Medicine|2020Cited by 320
The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) TransfusionsMaria Domenica Cappellini, Antonio Piga, Vip Viprakasit et al.|Blood|2018Cited by 14
Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive (<i>FLT3</i>-ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)Mark J. Levis, Kristy Burns, Karima Imadalou et al.|Blood|2024Cited by 5
Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) TransfusionsVip Viprakasit, Maria Domenica Cappellini, Olivier Hermine et al.|Blood|2019Cited by 3
AML-202 QuANTUM-First: Efficacy by Age in Newly Diagnosed (nd) Patients With FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication–Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML)Harry P. Erba, Pau Montesinos, Elżbieta Patkowska et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 1